Fulphila 6 MG/0.6 ML syringe 0.6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FU318
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,574
Award facts
- Contract value 100% obligated
- $29,574.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,574 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Fulphila 6 mg/0.6 mL syringes. The contract, with an ultimate completion date of December 3, 2025, represents a short-duration fulfillment order executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. This delivery order was awarded competitively without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Fulphila is a pegfilgrastim biosimilar used to support immune system function during chemotherapy treatment, reflecting the company's role in supplying specialized pharmaceutical products for military healthcare systems.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, holds a $999.999 billion prime IDC with DLA Troop Support Medical (SPE2DX) extending through December 2026, which serves as the underlying vehicle for this delivery order. The company's extensive federal contracting portfolio with the Defense Logistics Agency demonstrates its capacity to fulfill a wide range of pharmaceutical and medical supply requirements across multiple therapeutic domains for military and veteran healthcare programs. This delivery order exemplifies the operational flexibility of the DLA's pharmaceutical prime vendor model, enabling rapid procurement of critical specialty medications to support military medical operations.
Quick answers
Who was awarded contract SPE2DR26FU318?
SPE2DR26FU318 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DR26FU318 worth?
The government has obligated $29,574 on SPE2DR26FU318.
Is contract SPE2DR26FU318 an order under another contract?
Yes. SPE2DR26FU318 is a delivery order under SPE2DR25D1053, an indefinite delivery contract.
Was contract SPE2DR26FU318 competed?
The extent of competition for SPE2DR26FU318 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award